Proton pump inhibitors, commonly known as PPIs, are among the most widely used medications in the world, and for short-term use they’re generally safe and effective at treating heartburn, acid reflux, and ulcers. The concern starts when people stay on them for months or years, which millions do. Long-term PPI use has been linked to kidney problems, bone fractures, nutrient deficiencies, gut infections, and cardiovascular risks. Many of these associations come from large observational studies, meaning they show a pattern rather than definitive proof of cause and effect, but the cumulative evidence is serious enough that the FDA has issued multiple safety warnings.
They Block More Than Just Acid
PPIs work by shutting down the proton pumps in your stomach lining that produce hydrochloric acid. That’s helpful when you have a bleeding ulcer or severe reflux, but stomach acid does a lot more than cause heartburn. It’s your first line of defense against harmful bacteria in food and water. It activates enzymes that break down proteins. And it helps your body absorb essential nutrients like vitamin B12, iron, magnesium, and calcium. When you suppress acid production for weeks or months on end, you’re disrupting all of those processes simultaneously.
Nutrient Deficiencies Build Over Time
Vitamin B12 is one of the clearest examples. Your body needs stomach acid to activate an enzyme called pepsin, which separates B12 from the proteins in food. Without adequate acid, B12 stays locked to those proteins and passes through your digestive tract unabsorbed. Over months to years, this can lead to B12 deficiency, which causes fatigue, nerve tingling, memory problems, and anemia.
Iron absorption follows a similar pattern. About two-thirds of the iron in your diet is in a form that depends on stomach acid to become soluble enough for your intestines to take it up. Suppressing that acid can gradually deplete your iron stores.
Magnesium deficiency is perhaps the most concerning nutrient issue. The FDA issued a specific safety communication warning that prescription PPIs taken for longer than one year can cause dangerously low magnesium levels. Low magnesium can trigger muscle spasms, irregular heartbeat, and seizures. The FDA noted that over-the-counter PPIs, which are labeled for just 14 days of use up to three times per year, carry very little risk of this problem. The risk comes from prolonged use that far exceeds those directions.
Kidney Damage at Several Levels
The connection between PPIs and kidney problems is one of the most well-documented risks. PPIs can trigger an immune reaction in the kidneys called acute interstitial nephritis, an inflammatory condition affecting the kidney’s filtering structures. PPI users have roughly three times the incidence of this condition compared to non-users. If it goes unrecognized and the medication isn’t stopped, the inflammation can cause permanent scarring and progress to chronic kidney disease.
Beyond that acute reaction, PPIs are associated with a broader increase in chronic kidney disease risk. Multiple large studies have found that PPI users are 10 to 50 percent more likely to develop chronic kidney disease than non-users, even after adjusting for other health conditions. One study found that about 30 percent of people who recover from PPI-related acute kidney injury still go on to develop chronic kidney disease. The low magnesium levels caused by PPIs may accelerate this process by damaging blood vessel cells in the kidneys and promoting inflammation.
Bone Fracture Risk Increases With Duration
The FDA has also warned that PPIs may increase the risk of fractures in the hip, wrist, and spine, particularly at high doses or with use lasting a year or more. The likely mechanism involves impaired calcium absorption due to reduced stomach acid, though the exact pathway isn’t fully established.
The numbers from multiple studies paint a consistent picture. PPI use for more than one year is associated with roughly a 44 percent increased risk of hip fracture. That risk climbs with longer use: after four or more years, hip fracture risk increases by about 59 percent. One study found that after seven or more years of use, the risk of hip fracture was more than four times higher than in non-users. Even total fracture risk across all bone sites goes up by about 25 percent. The highest risk is seen in people taking high-dose prescriptions rather than occasional over-the-counter use.
Gut Infections and Bacterial Overgrowth
Stomach acid serves as a natural barrier against ingested pathogens. When PPIs suppress that barrier, harmful bacteria that would normally be killed in the stomach can survive and colonize the intestines. The most concerning of these is Clostridioides difficile, a bacterium that causes severe, sometimes life-threatening diarrhea.
The FDA reviewed 23 studies and found that PPI users had 1.4 to 2.75 times the risk of C. difficile infection compared to non-users. This is especially relevant for older adults, hospitalized patients, or anyone also taking antibiotics. PPI use has also been linked to higher rates of community-acquired pneumonia, likely because bacteria from the stomach can more easily travel upward into the lungs when acid levels are low.
Cardiovascular Concerns
Large cohort studies have linked PPI use to a higher risk of heart attack and ischemic stroke. This association holds up even in people who aren’t taking blood thinners or aspirin, which rules out the once-popular theory that PPIs were simply interfering with anti-clotting medications.
The leading explanation involves nitric oxide, a molecule that keeps blood vessels relaxed and flexible. PPIs appear to inhibit an enzyme that clears a compound called ADMA from the bloodstream. When ADMA accumulates, it blocks nitric oxide production, causing blood vessels to stiffen and function poorly. Research on long-term PPI users has found measurable reductions in blood vessel function consistent with this mechanism. The effect seems to be more relevant in people taking PPIs for longer than four weeks.
The Dementia Question Remains Unresolved
You may have seen headlines linking PPIs to dementia. The reality is mixed. A Taiwanese study reported a 22 percent increase in dementia risk among long-term users, and a 2023 study found higher dementia rates in people over 45 who used PPIs for more than 4.4 years. But a large prospective study of nearly 19,000 older adults in the United States and Australia found no significant association at all.
Mendelian randomization studies, which use genetic data to test for causal relationships, have also found no significant link. A 2024 analysis using this approach showed no association for the most commonly studied PPIs after statistical adjustments. The conflicting findings likely stem from confounding factors in observational research, such as the possibility that people prescribed long-term PPIs tend to be sicker overall. For now, the dementia link is unproven but not fully ruled out.
Rebound Acid Makes Them Hard to Stop
One of the most frustrating aspects of long-term PPI use is what happens when you try to quit. Your body responds to months of suppressed acid by ramping up its acid-producing machinery. Cells in the stomach lining that release the hormone gastrin multiply, as do the cells that produce acid in response to gastrin. When you stop the PPI, all of that extra capacity kicks in at once, flooding your stomach with more acid than you had before you ever started the medication.
This rebound acid hypersecretion typically starts 5 to 14 days after stopping, lasts around 4 to 5 days in most people, though some experience symptoms at 3 to 4 weeks after withdrawal. After more than a year of PPI use, the rebound period can persist for more than 8 weeks but generally resolves within 6 months. The cruel irony is that this rebound often mimics the original symptoms, convincing people they still need the medication. This cycle is a major reason why so many people remain on PPIs far longer than intended.
How to Taper Safely
Clinical guidelines recommend that most people should use PPIs for only 4 to 8 weeks. The American College of Gastroenterologists recommends an initial 8-week course for acid reflux, after which the medication should be stopped and the need for continued treatment reassessed. For ulcers, 2 to 12 weeks is typically sufficient. The people who genuinely need long-term PPIs are a relatively small group: those with Barrett’s esophagus, severe erosive esophagitis, or a history of bleeding stomach ulcers.
If you’ve been on a PPI for months or longer, stopping abruptly is likely to trigger rebound symptoms. Canadian clinical practice guidelines recommend a gradual approach: reducing from twice daily to once daily, then from a full dose to a half dose, then to every other day, and eventually stopping. Switching to on-demand use, where you only take the medication when symptoms flare, is another recommended strategy. An older class of acid reducers called H2 blockers can also serve as a bridge during the tapering process, since they reduce acid through a different mechanism and don’t cause the same rebound effect.
Over-the-counter PPIs were designed for short, infrequent courses: 14 days at a time, no more than three times per year. The FDA has acknowledged that many people use them well beyond these directions, either on their own or on a doctor’s advice, and that this constitutes off-label use with risks that the OTC labeling wasn’t designed to address.